ORTEXORTEX News
Tracking NKE? Get live short interest, options flow, and signals on ORTEX.Sign up free →
NK
Trader NoteNKE

Nike Shorts Build Ahead of October Earnings

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 3 min readdata as of 23 Sept 2026, 18:44

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit
ORTEX chart of NIKE, Inc. (NKE) share price and short interest (% of free float), six months to September 22, 2026
ORTEX data as of 23 Sept 2026, 18:44

NKE heads into its October 1 earnings report with short sellers adding aggressively, analysts cutting targets across the board, and the stock down 11% in a month — a setup that puts the recovery thesis under immediate pressure.

The short interest story is the week's sharpest signal. Bears have added meaningfully — SI climbed nearly 10% in a single week to 6.6% of the free float, representing around 78.8 million shares. The one-month build is even starker: shorts have grown 31.6% since late August, accelerating from roughly 59 million shares to nearly 79 million in five weeks. That is the most concentrated bearish positioning in several months and suggests a clear directional conviction ahead of the print. The borrow market, though, offers no sign of a squeeze: availability is comfortable at 621%, with plenty of shares remaining in the lending pool relative to those already borrowed, and cost to borrow is low at 0.45%. Shorts face no logistical friction adding further. Options positioning, meanwhile, has actually become slightly more bullish than usual — the put/call ratio at 0.72 is modestly below its 20-day average of 0.74, sitting closer to the 52-week low than the high. That divergence is notable: derivatives traders are not rushing for downside protection even as the short book grows.

The analyst community is delivering a near-uniform message of reduced expectations. This week alone, Oppenheimer's Brian Nagel cut his target from $60 to $52 while holding Outperform, and Barclays trimmed from $52 to $48. Both moves came on the day of writing. Stifel, UBS, Telsey, Citi, and Baird have all lowered targets in the past ten days, with Baird going further — downgrading to Neutral from Outperform and slashing from $70 to $44. Morgan Stanley reinstated coverage last week with an Underweight and a $31 target, the most bearish institutional view on the tape. Even the bulls are retreating to shorter flagpoles. The mean consensus price target sits at $47.32, implying roughly 31% upside from $36.10 — but the direction of travel on that number is sharply lower. The PE multiple has compressed to around 17x on a trailing basis, down nearly 2.5 turns over the past month, reflecting eroding confidence in near-term earnings power.

The bull case, as articulated by the remaining Outperform-rated analysts, rests on e-commerce momentum, a China recovery, and the brand's enduring strength in basketball and running. The bear case — and it has grown louder — centres on structural market share losses to challenger brands like ONON, which jumped nearly 10% this week alone, and the pace of Nike's operational reset. Challenger competition is not theoretical: ONON's 9.8% weekly gain against NKE's 0.3% decline captures the relative story in a single data point. BIRK and COLM also posted gains of 5.6% and 3.4% respectively on the week, suggesting the pressure on NKE is more company-specific than sector-wide.

Insider activity adds a layer of nuance worth noting. The 90-day net position is modestly negative at around -$771,000, driven by three EVP-level planned sales on September 9 executed under 10b5-1 programmes — the COO, Chief Legal Officer, and Chief Innovation Officer each sold small parcels at $37.59. Pre-arranged plan sales carry limited signalling value. The director-level grants on September 8 (including Tim Cook) are routine compensation awards, not open-market purchases. There is no discretionary insider buying visible in the data at current prices — the absence of which, given how far the stock has fallen, is itself a data point.

With earnings due October 1 and the short book at a multi-month high, the next report is less about whether Nike is growing and more about whether management can credibly reset the timeline on the turnaround — and whether that timeline is shorter or longer than an increasingly impatient Street now fears.

Against its own history

Short interest is at its highest level in at least a year.

Against its peers

Shares moved -0.3% over the past week against a median of +3.8% for its closest peers.

Stocks in this article

See the live data behind this article on ORTEX.

Open NKE on ORTEX →

How this article was generated

Generated
23 Sept 2026, 18:44
Data as of
23 Sept 2026, 18:44
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notes

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.